Hepatitis C Virus Infection: Clinical Trials

27 completed, 2 terminated, 1 unknown, 1 withdrawn. 31 Phase 2, 4 Phase 1, 1 Phase 3.

By phase and status

Phase	Trials	Status
Phase 2	31	Completed 27, Terminated 2, Unknown 1, Withdrawn 1
Phase 1	4	Completed 2, Terminated 1, Withdrawn 1
Phase 3	1	Completed 1

Follow Hepatitis C Virus Infection: new trials by email Literature Review of Hepatitis C Virus Infection trials Research Report on Hepatitis C Virus Infection

Trials (filtered) newest first · largest first

All 31 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects AT-777, Placebo, AT-527 - Hepatitis C, Hepatitis C, Chronic	Phase 1 / Phase 2	Withdrawn	Atea Pharmaceuticals, Inc.		2021-10-01	2022-06-08
Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection AT-527, Daclatasvir - Hepatitis C, Hepatitis C, Chronic	Phase 2	Completed	Atea Pharmaceuticals, Inc.	10	2019-06-20	2020-05-04
Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 2,3,6 Hepatitis C Virus Infection Patients Seraprevir, Sofosbuvir - Hepatitis C Virus Infection	Phase 2	Unknown	Ginkgopharma CO., LTD	36	2019-04-03	2019-10-01
Study to Investigate Pharmacokinetics, Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) Fixed Dose Combination (FDC) in Adolescents and Children With Chronic Hepatitis C Virus (HCV) Infection SOF/VEL/VOX - Hepatitis C Virus Infection	Phase 2	Terminated	Gilead Sciences	21	2019-01-28	2020-10-23
Ledipasvir/Sofosbuvir in Adults With Chronic Hepatitis C Virus (HCV) Infection Who Are on Dialysis for End Stage Renal Disease LDV/SOF - Hepatitis C Virus Infection	Phase 2	Completed	Gilead Sciences	95	2017-06-27	2020-03-02
Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children With Chronic HCV Infection SOF/VEL - Hepatitis C Virus Infection	Phase 2	Completed	Gilead Sciences	216	2017-01-26	2020-10-08
Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Participants With Chronic HCV Infection and Child-Pugh-Turcotte Class C Cirrhosis SOF/VEL, RBV - Hepatitis C Virus Infection	Phase 2	Completed	Gilead Sciences	32	2017-01-23	2020-03-02
Ombitasvir /Paritaprevir/Ritonavir Plus Ribavirin on HCV GT4 OBV/PTV/r) ± ribavirin (RBV) - Hepatitis C Virus Infection	Phase 1 / Phase 2	Completed	Beni-Suef University	100	2017-01-05	2020-05-12
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Participants Undergoing Cancer Chemotherapy LDV/SOF - Hepatitis C Virus Infection	Phase 2	Completed	Gilead Sciences	19	2016-08-28	2020-03-02
Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir FDC and Ribavirin in Participants With Chronic Genotype 3 HCV Infection and Cirrhosis SOF/VEL, RBV - Hepatitis C Virus Infection	Phase 2	Completed	Gilead Sciences	204	2016-07-29	2018-11-27
Sofosbuvir/Velpatasvir Fixed Dose Combination in Participants With Chronic Hepatitis C Virus Infection Who Have Received a Liver Transplant SOF/VEL - Hepatitis C Virus Infection	Phase 2	Completed	Gilead Sciences	79	2016-07-27	2018-11-14
Sofosbuvir/Velpatasvir Fixed-Dose Combination in HCV-Infected Adults Who Are Undergoing Liver Transplantation SOF/VEL - Hepatitis C Virus Infection	Phase 2	Completed	Gilead Sciences	9	2016-06-12	2019-02-06
Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen SOF/VEL/VOX, RBV - Hepatitis C Virus Infection	Phase 2	Completed	Gilead Sciences	49	2015-07-29	2019-02-25
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination Administered in Patients Infected With Chronic Genotype 1 or 4 HCV for Use in the Peri-Operative Liver Transplantation Setting LDV/SOF - Hepatitis C Virus Infection	Phase 2	Completed	Gilead Sciences	17	2015-05-22	2018-11-19
Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination Tablet With Ribavirin for 12 Weeks in Treatment-naive Adults With Chronic HCV Genotype 3 Infection LDV/SOF, RBV - Hepatitis C Virus Infection	Phase 2	Completed	Gilead Sciences	111	2015-04-01	2018-11-16
Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease LDV/SOF - Hepatitis C Virus Infection	Phase 2	Completed	Gilead Sciences	10	2015-03-02	2018-11-19
Sofosbuvir/Pegylated-interferon Plus Ribavirin With HCV Genotype 4 SOF/RBV/PegINFα-2 - Hepatitis C Virus Infection	Phase 1 / Phase 2	Completed	Beni-Suef University	99	2015-03-01	2020-05-11
Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV Infection VOX, SOF/VEL, RBV - Hepatitis C Virus Infection	Phase 2	Completed	Gilead Sciences	205	2015-02-17	2020-03-06
Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV Infection VOX, SOF/VEL - Hepatitis C Virus Infection	Phase 2	Completed	Gilead Sciences	128	2015-02-16	2020-03-03
Efficacy And Safety Of Sofosbuvir/Velpatasvir Fixed Dose Combination With Ribavirin in Chronic HCV Infected Adults Who Participated in a Prior Gilead Sponsored HCV Treatment Study SOF/VEL, RBV - Hepatitis C Virus Infection	Phase 2	Completed	Gilead Sciences	69	2014-12-01	2018-11-16

Showing 20 of 31. Sign in to see all of them.

Narrower conditions

Hepatitis C (31)  ·  Hepatitis C, Chronic (5)  ·  Liver Diseases (2)  ·  Acquired Immunodeficiency Syndrome (1)  ·  Anemia, Sickle Cell (1)  ·  Communicable Diseases (1)  ·  HIV Infections (1)  ·  Infections (1)  ·  RNA Virus Infections (1)  ·  Virus Diseases (1)

Broader conditions

Blood-Borne Infections (31)  ·  Digestive System Diseases (31)  ·  Flaviviridae Infections (31)  ·  Hepatitis (31)  ·  Hepatitis, Viral, Human (31)  ·  Communicable Diseases (30)  ·  Infections (30)  ·  RNA Virus Infections (30)  ·  Virus Diseases (30)  ·  Liver Diseases (29)  ·  Disease Attributes (6)  ·  Pathologic Processes (6)  ·  Pathological Conditions, Signs and Symptoms (6)  ·  Chronic Disease (5)  ·  Hepatitis, Chronic (5)

Interventions

ledipasvir, sofosbuvir drug combination (9)  ·  sofosbuvir-velpatasvir drug combination (8)  ·  Ribavirin (5)  ·  AT-511 (2)  ·  Sofosbuvir (2)  ·  daclatasvir (2)  ·  ombitasvir (2)  ·  paritaprevir (2)  ·  sofosbuvir velpatasvir voxilaprevir drug combination (2)  ·  voxilaprevir (2)  ·  ABT-072 (1)  ·  GS-9451 (1)  ·  Mifepristone (1)  ·  asunaprevir (1)  ·  dasabuvir (1)

Sponsors

Gilead Sciences (20)  ·  Atea Pharmaceuticals, Inc. (2)  ·  Beni-Suef University (2)  ·  AbbVie (1)  ·  AbbVie (prior sponsor, Abbott) (1)  ·  Bristol-Myers Squibb (1)  ·  Ginkgopharma CO., LTD (1)  ·  Hospital Clinic of Barcelona (1)  ·  PhytoHealth Corporation (1)  ·  VGX Pharmaceuticals, LLC (1)

Countries

United States (16)  ·  New Zealand (7)  ·  Italy (6)  ·  United Kingdom (6)  ·  Belgium (5)  ·  Australia (4)  ·  Germany (4)  ·  Spain (4)  ·  France (3)  ·  Puerto Rico (3)  ·  Taiwan (3)  ·  Austria (2)  ·  Canada (2)  ·  Poland (2)  ·  Argentina (1)

Top investigators

Mohammed Abdel-Gabbar, Ass. Prof (2)  ·  Alberto Sanchez-Fueyo, MD (1)  ·  Benedetta Massetto, MD (1)  ·  Bruce Bacon, M.D. (1)  ·  Chia-Yen Dai, M.D., M.S. (1)  ·  Daniel Cohen, MD (1)  ·  George Wu, MD (1)  ·  Giuseppe Tisone, MD (1)  ·  Marina Berenguer, MD (1)  ·  Ming-Lung Yu, M.D., Ph.D. (1)  ·  Pablo Tebas, M.D. (1)  ·  Robert Hyland, DPhil (1)  ·  Rolando Viani, MD (1)

Results publications

PMID 26743093, PMID 27486033, PMID 27486034, PMID 27842383, PMID 27919899, PMID 27959735, PMID 27997679, PMID 28412293, PMID 28535298, PMID 28543053, PMID 28957984, PMID 29193603, PMID 29958855, PMID 30070726, PMID 30324144, PMID 31220349, PMID 31222783, PMID 35149641, PMID 38644678

NIH funding

2016 (5), 2014 (3), 2019 (2), 2018 (1)